RU2348619C2 - Способ получения валсартана - Google Patents

Способ получения валсартана Download PDF

Info

Publication number
RU2348619C2
RU2348619C2 RU2005112444/04A RU2005112444A RU2348619C2 RU 2348619 C2 RU2348619 C2 RU 2348619C2 RU 2005112444/04 A RU2005112444/04 A RU 2005112444/04A RU 2005112444 A RU2005112444 A RU 2005112444A RU 2348619 C2 RU2348619 C2 RU 2348619C2
Authority
RU
Russia
Prior art keywords
formula
compound
methyl
salt
tetrazol
Prior art date
Application number
RU2005112444/04A
Other languages
English (en)
Russian (ru)
Other versions
RU2005112444A (ru
Inventor
Донасьенн ДЕННИ-ДИШЕР (FR)
Донасьенн ДЕННИ-ДИШЕР
Ханс ХИРТ (CH)
Ханс ХИРТ
Дан НЕВИЛЛЕ (CH)
Дан НЕВИЛЛЕ
Готтфрид ЗЕДЕЛЬМАЙЕР (DE)
Готтфрид ЗЕДЕЛЬМАЙЕР
Анита ШНИДЕР (CH)
Анита ШНИДЕР
Надин ДЕРРЬЕН (FR)
Надин ДЕРРЬЕН
Даниель КАУФМАНН (CH)
Даниель КАУФМАНН
Original Assignee
Новартис Аг
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=9944606&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=RU2348619(C2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Новартис Аг filed Critical Новартис Аг
Publication of RU2005112444A publication Critical patent/RU2005112444A/ru
Application granted granted Critical
Publication of RU2348619C2 publication Critical patent/RU2348619C2/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D257/00—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms
    • C07D257/02—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D257/04—Five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cardiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Hydrogenated Pyridines (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
RU2005112444/04A 2002-09-23 2003-09-22 Способ получения валсартана RU2348619C2 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0222056.4A GB0222056D0 (en) 2002-09-23 2002-09-23 Process for the manufacture of organic compounds
GB0222056.4 2002-09-23

Related Child Applications (1)

Application Number Title Priority Date Filing Date
RU2008133680/04A Division RU2412173C2 (ru) 2002-09-23 2003-09-22 Способ получения блокатора ангиотензинового рецептора

Publications (2)

Publication Number Publication Date
RU2005112444A RU2005112444A (ru) 2006-01-20
RU2348619C2 true RU2348619C2 (ru) 2009-03-10

Family

ID=9944606

Family Applications (2)

Application Number Title Priority Date Filing Date
RU2005112444/04A RU2348619C2 (ru) 2002-09-23 2003-09-22 Способ получения валсартана
RU2008133680/04A RU2412173C2 (ru) 2002-09-23 2003-09-22 Способ получения блокатора ангиотензинового рецептора

Family Applications After (1)

Application Number Title Priority Date Filing Date
RU2008133680/04A RU2412173C2 (ru) 2002-09-23 2003-09-22 Способ получения блокатора ангиотензинового рецептора

Country Status (29)

Country Link
US (3) US20060069268A1 (enExample)
EP (2) EP1546122B8 (enExample)
JP (2) JP4787498B2 (enExample)
KR (2) KR20050057529A (enExample)
CN (2) CN100357279C (enExample)
AR (1) AR041360A1 (enExample)
AU (1) AU2003270241B2 (enExample)
BR (1) BR0314132A (enExample)
CA (1) CA2502629A1 (enExample)
CY (1) CY1107878T1 (enExample)
DE (1) DE60317690T2 (enExample)
DK (1) DK1546122T3 (enExample)
EC (2) ECSP055695A (enExample)
ES (1) ES2295623T3 (enExample)
GB (1) GB0222056D0 (enExample)
IL (1) IL167426A (enExample)
MX (1) MXPA05003140A (enExample)
MY (1) MY138618A (enExample)
NO (2) NO20051970L (enExample)
NZ (2) NZ566863A (enExample)
PE (2) PE20050088A1 (enExample)
PL (1) PL374862A1 (enExample)
PT (1) PT1546122E (enExample)
RU (2) RU2348619C2 (enExample)
SG (1) SG155049A1 (enExample)
SI (1) SI1546122T1 (enExample)
TW (2) TWI329106B (enExample)
WO (1) WO2004026847A1 (enExample)
ZA (1) ZA200502159B (enExample)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7199144B2 (en) 2003-04-21 2007-04-03 Teva Pharmaceuticals Industries, Ltd. Process for the preparation of valsartan and intermediates thereof
DE602004013405T2 (de) 2003-03-17 2009-05-07 Teva Pharmaceutical Industries Ltd. Polymorphe formen von valsartan
WO2004094391A2 (en) * 2003-04-21 2004-11-04 Teva Pharmaceutical Industries Ltd. Process for the preparation of valsartan and intermediates thereof
EP1618097A1 (en) 2003-04-21 2006-01-25 Teva Pharmaceutical Industries Ltd Process for the preparation of valsartan
GB0316546D0 (en) 2003-07-15 2003-08-20 Novartis Ag Process for the manufacture of organic compounds
GB0402262D0 (en) * 2004-02-02 2004-03-10 Novartis Ag Process for the manufacture of organic compounds
EP1661891A1 (en) * 2004-11-30 2006-05-31 KRKA, D.D., Novo Mesto A process for the synthesis of valsartan
GB0514206D0 (en) * 2005-07-11 2005-08-17 Novartis Ag Organic compounds
ES2288376B1 (es) * 2005-10-20 2008-11-01 Inke, S.A. Procedimiento para la obtencion de intermedios utiles en la obtencion de un compuesto farmaceuticamente activo.
WO2007057919A2 (en) * 2005-10-25 2007-05-24 Alembic Limited An improved process for preparation of (s)-n-(1-carboxy-2-methyl-prop-1-yl)-n-pentanoyl-n-[2'-(1h-tetrazol-5-yl)biphenyl-4-ylmethyl]-amine
US7880015B2 (en) * 2006-07-03 2011-02-01 Aurobindo Pharma Ltd. Process for the preparation of angiotensin II antagonist
ES2315141B1 (es) * 2006-11-23 2009-12-22 Quimica Sintetica, S.A Procedimiento para la preparacion de cardesartan cilexetilo en forma cristalina.
CN101200455B (zh) * 2007-09-29 2010-08-18 泰兴市江神化工有限公司 沙坦类治疗高血压药物主环5-(4'-甲酰基联苯-2-基)-1h-四氮唑的制备方法
EP2090567A3 (en) 2008-02-13 2011-06-01 Ranbaxy Laboratories Limited Processes for the preparation of intermediates of valsartan
KR101012135B1 (ko) * 2008-12-18 2011-02-07 주식회사 대희화학 발사르탄 메틸 에스테르의 제조방법
EP2316821A1 (en) 2009-10-27 2011-05-04 Novartis AG Process for the manufacture of organic compounds
WO2012016969A1 (en) * 2010-08-03 2012-02-09 Novartis Ag Highly crystalline valsartan
CN102351804B (zh) * 2011-09-30 2013-07-31 浙江新赛科药业有限公司 一种缬沙坦消旋体的回收方法
CN103554047A (zh) * 2013-10-11 2014-02-05 镇江市高等专科学校 制备缬沙坦的方法
CN103923028B (zh) * 2014-05-04 2017-05-24 青岛雪洁助剂有限公司 一种缬沙坦甲酯的制备方法
CN104072433A (zh) * 2014-07-16 2014-10-01 南京正大天晴制药有限公司 一种缬沙坦的水解杂质化合物及其制备方法、检测方法和用途
CN104151199A (zh) * 2014-08-13 2014-11-19 苏州卫生职业技术学院 一种缬沙坦的合成方法
CN104844476B (zh) * 2015-04-03 2016-08-24 李凌 一种医药中间体联苯类化合物的合成方法
CN112014479A (zh) * 2019-05-28 2020-12-01 珠海润都制药股份有限公司 一种缬沙坦中正戊酰氯的检测方法
CN116655498B (zh) * 2023-05-24 2025-01-28 江苏阿尔法集团福瑞药业(宿迁)有限公司 一种沙库巴曲中间体的制备方法

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5468867A (en) * 1994-05-27 1995-11-21 Syntex (U.S.A.) Inc. Process for preparing1-butyl-2-[2'-(2H-tetrazol-5-yl)biphenyl-4-ylmethyl1-1H-indole-3-carboxylic acid
RU2091376C1 (ru) * 1987-05-22 1997-09-27 Е.И.Дюпон Де Немур Энд Компани Производные тетразола
US6071931A (en) * 1995-10-06 2000-06-06 Novartis Ag AT1 -receptor antagonists for preventing and treating postischemic renal failure and for protecting ischemic kidneys

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0443983B1 (de) * 1990-02-19 1996-02-28 Ciba-Geigy Ag Acylverbindungen
US5260325A (en) * 1991-08-19 1993-11-09 E. I. Du Pont De Nemours And Company Angiotensin II receptor blocking tertiary amides
FR2688503B1 (fr) * 1992-03-16 1994-05-06 Synthelabo Procede de preparation de derives de 2-(tetrazol-5-yl)-[1,1'-biphenyle].
EP0550313A1 (fr) * 1991-12-30 1993-07-07 Synthelabo Nouveaux dérivés de 2-(tétrazol-5-yl)-(1,1'-biphényle), leur préparation et leur utilisation comme intermédiaires de synthèse
US5284957A (en) * 1992-09-03 1994-02-08 Eli Lilly And Company Excitatory amino acid receptor antagonists
JPH08165292A (ja) * 1993-10-07 1996-06-25 Techno Res Kk アデニン誘導体、その製造法及び用途
US5412102A (en) * 1994-05-27 1995-05-02 Syntex (U.S.A.) Inc. Processes for preparing 1-butyl-2-[2'-(2H-tetrazol-5-yl) biphenyl-4-ylmethyl]-1H-indole-3-carboxylic acid
ATE176784T1 (de) * 1994-09-20 1999-03-15 Wakunaga Seiyaku Kk Verfahren zur herstellung von n- biphenylmethylthiadiazolin derivaten oder deren salzen sowie dafür benötigte zwischen verbindungen
EP0846117B1 (en) * 1995-06-07 2003-05-14 Wyeth Process for preparation of biphenyl derivatives
CN1137887C (zh) * 2000-04-07 2004-02-11 常州四药制药有限公司 一种合成缬沙坦的改进方法
CZ303389B6 (cs) * 2000-07-19 2012-08-29 Novartis Ag Sul valsartanu a farmaceutický prípravek obsahující tuto sul
JP4537678B2 (ja) * 2003-09-04 2010-09-01 住友化学株式会社 ２’−（１ｈ−テトラゾール−５−イル）ビフェニル−４−カルボアルデヒド結晶およびその製造方法
GB0402262D0 (en) * 2004-02-02 2004-03-10 Novartis Ag Process for the manufacture of organic compounds

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2091376C1 (ru) * 1987-05-22 1997-09-27 Е.И.Дюпон Де Немур Энд Компани Производные тетразола
US5468867A (en) * 1994-05-27 1995-11-21 Syntex (U.S.A.) Inc. Process for preparing1-butyl-2-[2'-(2H-tetrazol-5-yl)biphenyl-4-ylmethyl1-1H-indole-3-carboxylic acid
US6071931A (en) * 1995-10-06 2000-06-06 Novartis Ag AT1 -receptor antagonists for preventing and treating postischemic renal failure and for protecting ischemic kidneys

Also Published As

Publication number Publication date
AU2003270241A1 (en) 2004-04-08
ECSP055695A (es) 2005-05-30
PE20050088A1 (es) 2005-02-21
CY1107878T1 (el) 2013-06-19
NO20110856L (no) 2005-06-16
NZ566863A (en) 2009-08-28
SI1546122T1 (sl) 2008-04-30
JP2006502178A (ja) 2006-01-19
US20100249429A1 (en) 2010-09-30
MY138618A (en) 2009-07-31
US20060069268A1 (en) 2006-03-30
WO2004026847A1 (en) 2004-04-01
TW200413337A (en) 2004-08-01
BR0314132A (pt) 2005-06-28
TWI338003B (en) 2011-03-01
PE20091387A1 (es) 2009-10-13
CN100357279C (zh) 2007-12-26
JP2010254709A (ja) 2010-11-11
PT1546122E (pt) 2008-02-14
TWI329106B (en) 2010-08-21
IL167426A (en) 2010-11-30
EP1878729A1 (en) 2008-01-16
KR20110015703A (ko) 2011-02-16
DK1546122T3 (da) 2008-03-03
PL374862A1 (en) 2005-11-14
RU2005112444A (ru) 2006-01-20
EP1546122B1 (en) 2007-11-21
AU2003270241B2 (en) 2007-08-23
DE60317690T2 (de) 2008-10-30
EP1546122A1 (en) 2005-06-29
EP1546122B8 (en) 2008-05-28
KR20050057529A (ko) 2005-06-16
CA2502629A1 (en) 2004-04-01
CN1688556A (zh) 2005-10-26
GB0222056D0 (en) 2002-10-30
ECSP105695A (es) 2010-03-31
TW201016673A (en) 2010-05-01
SG155049A1 (en) 2009-09-30
DE60317690D1 (de) 2008-01-03
NO20051970L (no) 2005-06-16
US20090111995A1 (en) 2009-04-30
NZ538927A (en) 2008-05-30
CN101153027B (zh) 2010-08-18
ES2295623T3 (es) 2008-04-16
MXPA05003140A (es) 2005-06-22
JP4787498B2 (ja) 2011-10-05
RU2412173C2 (ru) 2011-02-20
RU2008133680A (ru) 2010-02-27
CN101153027A (zh) 2008-04-02
AR041360A1 (es) 2005-05-11
ZA200502159B (en) 2005-09-21
HK1079771A1 (en) 2006-04-13

Similar Documents

Publication Publication Date Title
RU2412173C2 (ru) Способ получения блокатора ангиотензинового рецептора
CN100475823C (zh) 从有机硼和有机铝叠氮化物制备四唑衍生物的方法
US5412102A (en) Processes for preparing 1-butyl-2-[2'-(2H-tetrazol-5-yl) biphenyl-4-ylmethyl]-1H-indole-3-carboxylic acid
EP1555260B1 (en) Phenyltetrazole compounds
WO2004111018A1 (en) A novel process for preparation of valsartan
US7439261B2 (en) Process for the preparation of valsartan and intermediates thereof
EP1777224A2 (en) A process for the preparation of angiotensin II antagonistic compounds
AU2007234598B2 (en) Process for the manufacture of Valsartan
HK1110599A (en) Intermediate for the manufacture of valsartan
EP2049527A2 (en) Preparation of irbesartan
HK1079771B (en) Process for the manufacture of valsartan
HK1093509B (en) Process for the preparation of tetrazole derivatives from organo boron and organo aluminium azides
HK1133657A (en) Process for the preparation of tetrazole derivatives from organo boron and organo aluminium azides
IL131709A (en) Processes for preparing 1-butyl-2- [2'- (2h-tetrazol-5-yl) biphenyl-4-ylmethyl]-1h-indole-3-carboxylic acid

Legal Events

Date Code Title Description
MM4A The patent is invalid due to non-payment of fees

Effective date: 20120923